MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

EG00229

CAS No. : 1210945-69-9

產(chǎn)品活性：EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC₅₀ of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2.

研究領(lǐng)域：Immunology/Inflammation

作用靶點(diǎn)：Complement System

In Vitro: EG00229 (Compound 2; 0-100 μM; 48 hours; A549 cells) treatment causes a significant reduction in cell viability over a 48 hours incubation.
EG00229 (Compound 2) demonstrates inhibition of VEGF-A binding to NRP1 and attenuates VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells is also observed in HUVECs.
EG00229 (Compound 2) selectively inhibits radiolabeled ¹²⁵I-VEGF-A binding to porcine aortic endothelial (PAE)/NRP1, but not VEGFR2-expressing cells, with an IC₅₀ of 8 μM. EG00229 also inhibits VEGF-A binding to lung carcinoma A549 and prostate carcinoma DU145 cells, which express NRP1, but not VEGFR1 and VEGFR2, with similar potency. Binding of VEGF-A to human umbilical vein endothelial cells (HUVECs), which express VEGFR2, VEGFR1, and NRP1, is also inhibited by EG00229 with an IC₅₀ of 23 μM.

In Vivo: EG00229 (0-10 mg/kg; intraperitoneal injection; three times per week; for 4 weeks; NSG mice) treatment substantially reduces tumor growth and visible vascularization.

相關(guān)產(chǎn)品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Anti-Cancer Compound Library  |  Peptidomimetic Library  |  Protein-protein Interaction Inhibitor Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  FD-IN-1  |  CP-447697  |  Factor B-IN-2  |  Ravulizumab  |  NRP1 antagonist 1  |  ADH-503  |  Avacincaptad pegol  |  NRP1 antagonist 2  |  Dexamethasone-d₄  |  Complement C1s-IN-1  |  Complement C5-IN-1  |  Pozelimab  |  Phaseoloidin  |  Pexelizumab  |  Avdoralimab  |  POT-4 TFA  |  EG01377  |  Non-PEGylated/naked ARC186  |  Certepetide  |  ATWLPPR Peptide TFA  |  Tesidolumab  |  Gefurulimab  |  Compstatin  |  Cyclosporin A  |  Cemdisiran, terminal sugar modification-  |  AMY-101 acetate  |  Factor D inhibitor 6  |  BCX 1470

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點(diǎn)擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫，我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實(shí)驗(yàn)驗(yàn)證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展，為您提供全球新的活性化合物；
•   與世界各大制藥公司及著名科研機(jī)構(gòu)建立了長期的合作。